Stada invests €20M in Serbian Hemofarm plant expansion

Stada Group is investing an additional €20 million in its Serbian subsidiary Hemofarm in Vršac, continuing a two-decade relationship. The investment signals confidence in the local manufacturing base, though details on capacity or product lines are unspecified. This is a routine corporate capital expenditure with limited macro impact.